STOCK TITAN

Vir Biotechnology prices $150M stock offering

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Vir Biotechnology, Inc. (VIR) priced an underwritten public offering of 15,000,000 common shares at $10.00 per share. The company expects gross proceeds of $150 million and net proceeds of approximately $140.4 million after underwriting discounts, commissions and estimated offering expenses.

Underwriters may purchase up to an additional 2,250,000 shares under a 30-day option. If exercised in full, Vir expects net proceeds of approximately $161.5 million. Closing is expected on November 16, 2026, subject to customary closing conditions.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Common shares offered 15,000,000 shares Priced offering
Public offering price $10.00 per share Priced offering
Gross proceeds $150 million Before underwriting discounts, commissions and estimated offering expenses
Net proceeds Approximately $140.4 million After underwriting discounts, commissions and estimated offering expenses
Additional shares underwriters may purchase Up to 2,250,000 shares Under a 30-day option
Net proceeds if option fully exercised Approximately $161.5 million After underwriting discounts, commissions and estimated offering expenses
Expected closing date November 16, 2026 Subject to customary closing conditions
underwriting agreement technical
"entered into an underwriting agreement"
An underwriting agreement is a contract where a company selling new stocks or bonds hires financial firms to buy those securities and resell them to investors. It matters because the agreement sets the offering price, number of securities, fees and which party bears the risk if sales fall short—think of it as a promise that the sale will happen and a roadmap investors can use to understand how the new securities reach the market.
underwriting discounts and commissions financial
"after deducting underwriting discounts and commissions"
Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.
gross proceeds financial
"gross proceeds to Vir Biotechnology from the offering"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.
net proceeds financial
"Vir Bio expects to receive net proceeds"
The amount of money a company actually keeps from a sale or fundraising after paying all direct costs and fees, similar to take-home pay after taxes and deductions. Investors care because net proceeds determine how much cash is available for things that affect value—paying debt, funding projects, buying assets, or returning money to shareholders—so it influences future growth potential and financial health.
bookrunning managers technical
"acting as bookrunning managers for the offering"
Lead banks that organize and manage a new stock or bond offering, coordinating other banks, setting the initial sale price, collecting investor orders and deciding how many shares each buyer receives. Think of them as the project manager and ticket-seller for a public offering — their pricing, allocations and ability to sell the issue directly affect how successful the offering is and how the security performs for investors afterward.
customary closing conditions technical
"subject to customary closing conditions"
"Customary closing conditions" are standard rules or checks that must be met before a business deal can be finalized, like making sure all paperwork is in order or that certain approvals are obtained. They matter because they help protect both parties, ensuring everything is in place and reducing the risk of surprises or problems after the deal is closed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares is VIR offering and at what price?

Vir priced an offering of 15,000,000 common shares at $10.00 per share. Underwriters have a 30-day option to purchase up to an additional 2,250,000 shares at the public offering price, less underwriting discounts and commissions.

How much does VIR expect to raise in the offering?

Vir expects gross proceeds of $150 million before underwriting discounts, commissions and estimated offering expenses, and net proceeds of approximately $140.4 million. If underwriters exercise their option in full, expected net proceeds are approximately $161.5 million.

When is VIR's offering expected to close?

Closing is expected on November 16, 2026, subject to customary closing conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001706431 0001706431 2026-11-12 2026-11-12
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): November 12, 2026

Vir Biotechnology, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39083   81-2730369
(State or Other Jurisdiction
of Incorporation)
 

(Commission

File Number)

  (IRS Employer
Identification No.)

 

1800 Owens Street, Suite 900  
San Francisco, California   94158
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (415) 906-4324

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common stock, $0.0001 par value    VIR    Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 1.01.

Entry into a Material Definitive Agreement.

On November 12, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Leerink Partners LLC, Morgan Stanley & Co. LLC and Evercore Group L.L.C., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 15,000,000 shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $10.00 per share (the Offering). The Offering is expected to close on November 16, 2026, subject to the satisfaction of customary closing conditions.

Pursuant to the terms of the Underwriting Agreement, Vir Bio granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,250,000 shares of Common Stock at the public offering price.

Vir Bio expects to receive net proceeds from the Offering of approximately $140.4 million, or approximately $161.5 million if the Underwriters exercise in full their option to purchase additional shares, after deducting underwriting discounts and commissions and estimated Offering expenses.

The shares are being offered and sold by means of an effective registration statement on Form S-3ASR, including a base prospectus, filed with the U.S. Securities and Exchange Commission on November 12, 2026 (File No. 333-299995), and a prospectus supplement dated November 12, 2026.

The Underwriting Agreement contains customary representations, warranties and covenants by Vir Bio, customary conditions to closing and indemnification obligations of Vir Bio and the Underwriters against certain liabilities. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates and were solely for the benefit of the parties to such agreement. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to a copy of the Underwriting Agreement, which is filed herewith as Exhibit 1.1 and is incorporated herein by reference.

The legal opinion, including the related consent, of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP relating to the validity of the shares of the Common Stock in the Offering is filed as Exhibit 5.1 hereto.

 

Item 8.01

Other Events.

On November 12, 2026, the Company issued a press release to announce a proposed offering of Common Stock pursuant to the Registration Statement (the Offering Press Release). A copy of the Offering Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On November 12, 2026, the Company also issued a press release to announce that it had priced the Offering (the Pricing Press Release). A copy of the Pricing Press Release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.


Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

No.

   Description
1.1    Underwriting Agreement dated as of November 12, 2026, among Vir Biotechnology, Inc. and Leerink Partners LLC, Morgan Stanley & Co. LLC and Evercore Group L.L.C., as representatives of the underwriters named therein.
5.1    Opinion and Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP.
23.1    Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included in Exhibit 5.1).
99.1    Press release issued by Vir Biotechnology, Inc., dated November 12, 2026.
99.2    Press release issued by Vir Biotechnology, Inc., dated November 12, 2026.
104    Cover Page Interactive Data File (formatted as inline XBRL)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      VIR BIOTECHNOLOGY, INC.
Date: November 13, 2026     By:  

/s/ Marianne De Backer

     

Marianne De Backer, M.Sc., Ph.D., MBA

Chief Executive Officer

Exhibit 99.1

 

LOGO

Vir Biotechnology Announces Proposed Public Offering

SAN FRANCISCO, November 12, 2026 – Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock to be sold in the offering at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering will be offered by Vir Biotechnology. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Leerink Partners, Morgan Stanley and Evercore ISI are acting as bookrunning managers for the offering. Raymond James is acting as co-manager for the offering.

The shares described above are being offered pursuant to a registration statement that was filed with the U.S. Securities and Exchange Commission (the SEC) on November 12, 2026 and became automatically effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and may be obtained, when available, by contacting: Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com; or by accessing the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of oncologic malignancies.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “should,” “could,” “may,” “might,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding: the anticipated size and terms of the offering, the ability to complete the offering, whether or not the underwriters ultimately purchase any additional shares; risks and uncertainties related to the market and other conditions; and any assumptions underlying any of the foregoing. Many factors may cause differences between current expectations and actual results, including, without limitation, market and other conditions, including as may be impacted by geopolitical changes and other external factors that are beyond Vir Biotechnology’s or the underwriters’ control; the ability to complete the offering; and the satisfaction of the customary closing conditions related to the offering. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results, and the variations may be material. You are cautioned not to place undue reliance on these forward-looking statements, which are based on Vir Biotechnology’s available information, expectations and assumptions as of the date of this press release. Other factors that may cause Vir Biotechnology’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the section titled “Risk Factors” of Vir Biotechnology’s Quarterly Report on Form 10-Q, filed with the SEC on November 4, 2026, and in the preliminary prospectus supplement relating to the proposed offering. Except as required by law, Vir Biotechnology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Vir Biotechnology has exclusive rights to the universal PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

Media

Caren Scannell

Director, Communications

cscannell@vir.bio

Investors

Kiki Patel, PharmD

Head of Investor Relations

kpatel@vir.bio

Source: Vir Biotechnology, Inc.

Exhibit 99.2

 

LOGO

Vir Biotechnology Announces Pricing of Public Offering

SAN FRANCISCO, November 12, 2026—Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be $150 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Vir Biotechnology has granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being sold by Vir Biotechnology. Closing of the offering is expected to occur on November 16, 2026, subject to customary closing conditions.

Leerink Partners, Morgan Stanley and Evercore ISI are acting as bookrunning managers for the offering. Raymond James is acting as co-manager for the offering.

The shares described above are being offered pursuant to a registration statement that was filed with the U.S. Securities and Exchange Commission (the SEC) on November 12, 2026 and became automatically effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on November 12, 2026. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, by contacting: Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com; or by accessing the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of oncologic malignancies.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “should,” “could,” “may,” “might,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the completion of the public offering. Many factors may cause differences between current expectations and actual results, including, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results, and the variations may be material. You are cautioned not to place undue reliance on these forward-looking statements, which are based on Vir Biotechnology’s available information, expectations and assumptions as of the date of this press release. Other factors that may cause Vir Biotechnology’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the section titled “Risk Factors” of Vir Biotechnology’s Quarterly Report on Form 10-Q, filed with the SEC on November 4, 2026, and in the preliminary prospectus supplement relating to the offering. Except as required by law, Vir Biotechnology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Vir Biotechnology has exclusive rights to the universal PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

Media

Caren Scannell

Director, Communications

cscannell@vir.bio

Investors

Kiki Patel, PharmD

Head of Investor Relations

kpatel@vir.bio

Source: Vir Biotechnology, Inc.

Filing Exhibits & Attachments

7 documents

Keep reading